YEEDOZENCOM Helped Qianjin Xieli to Pass the Consistency Evaluation of Generic Drugs of Entecavir Dispersible Tablets

     Recently, Qianjin Xieli received "Drug Supplement Application Approval" of its Entecavir Dispersible Tablets, which approved and issued by NMPA. The product is deemed to have passed the Consistency Evaluation of the Quality and Efficacy of Generic Drugs.

   
     Entecavir Dispersible Tablet is the first-line drug for treatment of hepatitis B virus. Qianjin Xieli obtained the Marketing Authorization of Entecavir Dispersible Tablets on September 22, 2014. The quality of the product has been consistent since it was put on the market. The company has conducted a comprehensive comparative study with the reference drug (Baraclude). The results show that the product is equivalent to the innovator product in terms of in-vitro quality and in-vivo efficacy.
     
     Passing the Consistency Evaluation of Generic Drugs of Entecavir Dispersible Tablets is an affirmation of the product quality and efficacy of Qianjin Xieli. It will also inspire the company to focus more on product innovation and product quality and will provide strong technical support for the company's sustainable development.

About Qianjin Xieli

      Hunan Qianjin Xieli Pharmaceutical Co., Ltd. is a pharmaceutical company controlled by Zhuzhou Qianjin Pharmaceutical Co., Ltd. and Zhuzhou State-owned Assets Investment Holding Group Co., Ltd. and is located in Zhuzhou City, Hunan Province. Qianjin Xieli is a new pharmaceutical company that engaged in the production of Chinese patent medicine, synthetic drugs and health care products. Since its establishment in 2003, the company has built eight production lines of six major dosage forms, including API, pretreatment of traditional Chinese medicine, tablets, oral solution, concentracted decoctions, capsules and granules. All of them have passed the new version of GMP certification. The facilities and equipment are advanced and are at the domestic front.

About YEEDOZENCOM